{'messages': [HumanMessage(content='respond with .', additional_kwargs={}, response_metadata={}, id='1020ac44-fd4e-4a06-b4f9-9a7af43fef16'), AIMessage(content="As of today, July 16, 2025, there are no expectations of a new Alzheimer's drug approval this year [k2med](https://vertexaisearch.cloud.google.com/id/0-6). However, several promising drug candidates are in Phase 3 trials with results expected this year and next [k2med](https://vertexaisearch.cloud.google.com/id/0-6). These include Alzheon's valiltramiprosate, AriBio's AR1001, and Eli Lilly's remternetug [k2med](https://vertexaisearch.cloud.google.com/id/0-6). Semaglutide is also undergoing trials, with results expected by September 2025 [alzheimers](https://vertexaisearch.cloud.google.com/id/0-7).\n\nHere's a comparison of these drugs to the already approved donanemab (Kisunla) and lecanemab (LEQEMBI):\n\n*   **Donanemab (Kisunla):** Approved by the FDA in 2024 for mild cognitive impairment or mild dementia, Kisunla is a monoclonal antibody administered intravenously every four weeks that targets amyloid plaques in the brain [fda](https://vertexaisearch.cloud.google.com/id/0-0) [alzra](https://vertexaisearch.cloud.google.com/id/0-2) [practicalneurology](https://vertexaisearch.cloud.google.com/id/0-3).\n*   **Lecanemab (LEQEMBI):** Approved in July 2023, LEQEMBI is also administered intravenously and can slow cognitive decline in early-stage Alzheimer's [alzint](https://vertexaisearch.cloud.google.com/id/0-1) [stonybrookmedicine](https://vertexaisearch.cloud.google.com/id/0-5). Eisai's application for a subcutaneous autoinjector for weekly maintenance dosing is under FDA review, with a decision expected by August 31, 2025 [eisai](https://vertexaisearch.cloud.google.com/id/0-4).\n\n**Investigational Alzheimer's Drugs:**\n\n*   **Valiltramiprosate (ALZ-801):** This is an oral prodrug of tramiprosate [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1) [nih](https://vertexaisearch.cloud.google.com/id/1-2). It binds to amyloid-beta (Aβ42) monomers, preventing their aggregation into toxic oligomers [nih](https://vertexaisearch.cloud.google.com/id/1-2) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1) [patsnap](https://vertexaisearch.cloud.google.com/id/1-3) [alzheon](https://vertexaisearch.cloud.google.com/id/1-4). Advantages include oral administration [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [alzheon](https://vertexaisearch.cloud.google.com/id/1-4), a potentially better safety profile regarding ARIA [nih](https://vertexaisearch.cloud.google.com/id/1-6) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [firstwordpharma](https://vertexaisearch.cloud.google.com/id/1-7), and potential for APOE4 homozygotes [nih](https://vertexaisearch.cloud.google.com/id/1-6) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-8) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [acnr](https://vertexaisearch.cloud.google.com/id/1-9). It also targets the formation of soluble amyloid aggregates early in the amyloid cascade [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-8) [firstwordpharma](https://vertexaisearch.cloud.google.com/id/1-7).\n*   **AR1001:** This is a selective phosphodiesterase 5 (PDE5) inhibitor [researchgate](https://vertexaisearch.cloud.google.com/id/1-10) [nih](https://vertexaisearch.cloud.google.com/id/1-11). It increases cGMP levels, promoting neuronal cell survival [researchgate](https://vertexaisearch.cloud.google.com/id/1-10) [nih](https://vertexaisearch.cloud.google.com/id/1-11) [alzdiscovery](https://vertexaisearch.cloud.google.com/id/1-12). It is a polypharmacological agent [researchgate](https://vertexaisearch.cloud.google.com/id/1-10) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-13) [neurologylive](https://vertexaisearch.cloud.google.com/id/1-14) and is orally available [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1].\n*   **Remternetug:** This is a monoclonal antibody designed to remove aggregated amyloid plaques [clinrol](https://vertexaisearch.cloud.google.com/id/1-15) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-16) [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17) [innovareacademics](https://vertexaisearch.cloud.google.com/id/1-18) [beingpatient](https://vertexaisearch.cloud.google.com/id/1-19). It may offer more robust plaque removal than donanemab [clinrol](https://vertexaisearch.cloud.google.com/id/1-15) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-16) [syenza](https://vertexaisearch.cloud.google.com/id/1-23) [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17). Remternetug is being tested for both intravenous and subcutaneous administration [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17).\n\nBoth donanemab and lecanemab are associated with side effects, most commonly ARIA [mylocalinfusion](https://vertexaisearch.cloud.google.com/id/1-26) [alzheimersresearchuk](https://vertexaisearch.cloud.google.com/id/1-28).", additional_kwargs={}, response_metadata={}, id='dcf537a1-7ec2-412f-a314-9dc42d7b7e23')], 'search_query': ["new drugs for the treatment of Alzheimer's disease approved by the FDA in 2024 or 2025", "What are the specific mechanisms of action of valiltramiprosate, AR1001, and remternetug in treating Alzheimer's disease, and what are their potential advantages over existing treatments like donanemab and lecanemab?"], 'web_research_result': ["In 2024, the FDA approved Kisunla (donanemab-azbt) injection for the treatment of Alzheimer's disease [fda](https://vertexaisearch.cloud.google.com/id/0-0). Kisunla is intended for patients with mild cognitive impairment or mild dementia [fda](https://vertexaisearch.cloud.google.com/id/0-0). It is administered intravenously every four weeks [fda](https://vertexaisearch.cloud.google.com/id/0-0). Donanemab is the second traditional approval of an Alzheimer's treatment by the FDA, the first being Leqembi (lecanemab) in July 2023 [alzint](https://vertexaisearch.cloud.google.com/id/0-1). Kisunla is a monoclonal antibody that targets amyloid plaques in the brain [alzra](https://vertexaisearch.cloud.google.com/id/0-2) [practicalneurology](https://vertexaisearch.cloud.google.com/id/0-3).\n\nEisai's Supplemental Biologics License Application (BLA) for the LEQEMBI subcutaneous autoinjector for weekly maintenance dosing was accepted by the FDA in January 2025, with a PDUFA action date set for August 31, 2025 [eisai](https://vertexaisearch.cloud.google.com/id/0-4). LEQEMBI is already approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE, Great Britain, Mexico, and Macau [eisai](https://vertexaisearch.cloud.google.com/id/0-4). Lecanemab (Leqembi) and donanemab (Kisunla) are administered intravenously and can slow cognitive decline in people diagnosed with early-stage Alzheimer's [stonybrookmedicine](https://vertexaisearch.cloud.google.com/id/0-5).\n\nBased on the status of drugs in the development pipeline, there are no expectations of another new Alzheimer's drug approval in 2025 [k2med](https://vertexaisearch.cloud.google.com/id/0-6). However, several promising drug candidates are in Phase 3 trials, with results expected this year and next [k2med](https://vertexaisearch.cloud.google.com/id/0-6). These drugs are being tested to treat people with mild cognitive impairment or early Alzheimer's disease and, unlike current treatments, most are in pill form [k2med](https://vertexaisearch.cloud.google.com/id/0-6). Some of the drugs to watch include Alzheon's valiltramiprosate, AriBio's AR1001, and Eli Lilly's remternetug [k2med](https://vertexaisearch.cloud.google.com/id/0-6). Semaglutide is also undergoing trials, with results expected by September 2025 [alzheimers](https://vertexaisearch.cloud.google.com/id/0-7).\n", "Here's a breakdown of the mechanisms of action of valiltramiprosate, AR1001, and remternetug in treating Alzheimer's disease, and their potential advantages over existing treatments like donanemab and lecanemab:\n\n**1. Valiltramiprosate (ALZ-801)**\n\n*   **Mechanism of Action:** Valiltramiprosate is an oral prodrug of tramiprosate [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1) [nih](https://vertexaisearch.cloud.google.com/id/1-2). Its active metabolites, including tramiprosate and 3-sulfopropanoic acid, bind to amyloid-beta (Aβ42) monomers. [nih](https://vertexaisearch.cloud.google.com/id/1-2) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1) This binding stabilizes the monomers, preventing their aggregation and oligomerization into toxic oligomers, which are believed to be a key driver of Alzheimer's disease. [patsnap](https://vertexaisearch.cloud.google.com/id/1-3) [nih](https://vertexaisearch.cloud.google.com/id/1-2) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [alzheon](https://vertexaisearch.cloud.google.com/id/1-4) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1) Valiltramiprosate's mechanism of action involves multiple molecules binding to amyloid monomers, stabilizing their shape and blocking the formation of neurotoxic oligomers. [alzheon](https://vertexaisearch.cloud.google.com/id/1-4)\n*   **Potential Advantages:**\n    *   **Oral Administration:** Valiltramiprosate is administered orally, offering a more convenient route compared to the intravenous infusions required for donanemab and lecanemab. [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [alzheon](https://vertexaisearch.cloud.google.com/id/1-4)\n    *   **Safety Profile:** Valiltramiprosate has not been associated with an increased risk of amyloid-related imaging abnormalities (ARIA), a known side effect of anti-amyloid monoclonal antibodies like donanemab and lecanemab. [nih](https://vertexaisearch.cloud.google.com/id/1-6) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [firstwordpharma](https://vertexaisearch.cloud.google.com/id/1-7)\n    *   **Targeting APOE4 Homozygotes:** Valiltramiprosate is being investigated for its potential in APOE ε4/ε4 homozygotes, a population at high risk for Alzheimer's disease and ARIA, and for whom some regulators limit the use of donanemab and lecanemab.\n  [nih](https://vertexaisearch.cloud.google.com/id/1-6) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-8) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [acnr](https://vertexaisearch.cloud.google.com/id/1-9)   *   **Early Intervention:** Valiltramiprosate acts early in the amyloid cascade, targeting the formation of soluble amyloid aggregates, unlike donanemab and lecanemab, which target insoluble plaques.\n  [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-8) [firstwordpharma](https://vertexaisearch.cloud.google.com/id/1-7)   *   **Neuroprotection:** Valiltramiprosate has demonstrated potential neuroprotective effects, including brain structure preservation and reduced hippocampal atrophy.\n* [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [firstwordpharma](https://vertexaisearch.cloud.google.com/id/1-7)   **Efficacy:**\n    *   A Phase III trial in APOE ε4 homozygotes did not meet its primary endpoint. Ho [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1) [nih](https://vertexaisearch.cloud.google.com/id/1-2)wever, a pre-specified analysis of the mild cognitive impairment (MCI) subgroup showed significant benefits on cognitive assessments.\n   [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [firstwordpharma](https://vertexaisearch.cloud.google.com/id/1-7) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1)  *   In the MCI population, valiltramiprosate treatment also resulted in significant improvements in Disability Assessment for Dementia (DAD) score, and clinically meaningful effects were also seen across the Clinical Dementia Rating – Sum of Boxes (CDR-SB) scores, mini-mental state examination (MMSE) scores, and Amsterdam – Instrumental Activities of Daily Living (A-IADL) scores.\n    *  [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5)  Imaging also revealed nominally significant reductions in brain shrinkage in MCI patients.\n\n**2.  [firstwordpharma](https://vertexaisearch.cloud.google.com/id/1-7)AR1001**\n\n*   **Mechanism of Action:** AR1001 is a highly selective phosphodiesterase 5 (PDE5) inhibitor. It inc [researchgate](https://vertexaisearch.cloud.google.com/id/1-10) [nih](https://vertexaisearch.cloud.google.com/id/1-11)reases levels of cyclic guanosine monophosphate (cGMP) and activates the cGMP/cAMP response element-binding protein (CREB) cascade, promoting neuronal cell survival. AR1001 [researchgate](https://vertexaisearch.cloud.google.com/id/1-10) [nih](https://vertexaisearch.cloud.google.com/id/1-11) [alzdiscovery](https://vertexaisearch.cloud.google.com/id/1-12) also downregulates Glucocorticoid Receptor (GR) transcriptional activity, reducing the expression of APP, BACE1, and Dickkopf-1 (Dkk1). Additi [researchgate](https://vertexaisearch.cloud.google.com/id/1-10)onally, AR1001 has been shown to disrupt pre-formed Aβ42 fibrils in vitro and reduce Aβ plaque deposition by activating autophagy.\n*   **Po [researchgate](https://vertexaisearch.cloud.google.com/id/1-10)tential Advantages:**\n    *   **Polypharmacological Agent:** AR1001 acts through multiple mechanisms, including promoting neuronal cell survival and inhibiting Aβ accumulation.\n    *   * [researchgate](https://vertexaisearch.cloud.google.com/id/1-10) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-13) [neurologylive](https://vertexaisearch.cloud.google.com/id/1-14)*Oral Administration:** AR1001 is an orally available drug.\n    *   * [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [tandfonline](https://vertexaisearch.cloud.google.com/id/1-1)*Blood Brain Barrier Penetration:** AR1001 has superior blood brain barrier penetrance.\n    *   * [alzdiscovery](https://vertexaisearch.cloud.google.com/id/1-12)*Safety:** AR1001 was well-tolerated in a yearlong clinical trial in AD patients.\n*   **Eff [alzdiscovery](https://vertexaisearch.cloud.google.com/id/1-12)icacy:**\n    *   AR1001 has shown potential evidence of promoting neuronal cell survival in AD during early-stage studies.\n    *   A [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-13)R1001 significantly increased hippocampal cGMP and BDNF at doses of 6 and 9 mg/kg QD.\n    *   A [nih](https://vertexaisearch.cloud.google.com/id/1-11)R1001 had pronounced effects in recovery of cognitive functions in a transgenic mouse model of AD at a dose equivalent to that being tested in the Phase 3 trial in early AD patients.\n    *   A [nih](https://vertexaisearch.cloud.google.com/id/1-11)R1001 was associated with a decrease in p-tau 181 levels.\n\n**3. Rem [neurologylive](https://vertexaisearch.cloud.google.com/id/1-14)ternetug**\n\n*   **Mechanism of Action:** Remternetug is a monoclonal antibody designed to target and remove aggregated amyloid plaques, a key pathological hallmark of Alzheimer's disease, via microglial-mediated clearance. It binds  [clinrol](https://vertexaisearch.cloud.google.com/id/1-15) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-16) [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17) [innovareacademics](https://vertexaisearch.cloud.google.com/id/1-18) [beingpatient](https://vertexaisearch.cloud.google.com/id/1-19)to a specific region of the toxic amyloid protein, attracting immune cells to clear the plaques. Remternet [beingpatient](https://vertexaisearch.cloud.google.com/id/1-19) [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17)ug targets N-terminal pyroglutamated Aβ.\n*   **Pote [innovareacademics](https://vertexaisearch.cloud.google.com/id/1-18)ntial Advantages:**\n    *   **Effective Plaque Removal:** Remternetug has demonstrated the ability to reduce brain amyloid plaque. Some data  [clinrol](https://vertexaisearch.cloud.google.com/id/1-15) [clinicaltrials](https://vertexaisearch.cloud.google.com/id/1-16)suggests it may provide more robust plaque removal than donanemab.\n    *   ** [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17)Subcutaneous Dosing:** Remternetug is being tested in clinical trials for both intravenous and subcutaneous administration, potentially offering a more convenient option than intravenous infusions.\n*   **Effi [everyone](https://vertexaisearch.cloud.google.com/id/1-20) [pharmaceutical-journal](https://vertexaisearch.cloud.google.com/id/1-21) [beingpatient](https://vertexaisearch.cloud.google.com/id/1-19) [alzheimers](https://vertexaisearch.cloud.google.com/id/1-22)cacy:**\n    *   Early trial data suggests significant amyloid plaque clearance within six months.\n    *   In [syenza](https://vertexaisearch.cloud.google.com/id/1-23) one study, 75% of participants treated with remternetug had amyloid cleared from their brains after 6 months, compared to 40% in a donanemab trial.\n*   **Safe [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17) [everyone](https://vertexaisearch.cloud.google.com/id/1-20)ty:**\n    *   Remternetug is associated with ARIA, including brain swelling.\n\n**4. Dona [syenza](https://vertexaisearch.cloud.google.com/id/1-23) [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17)nemab and Lecanemab**\n\n*   **Mechanism of Action:** Donanemab and lecanemab are monoclonal antibodies that target amyloid-beta plaques in the brain. Lecanemab  [drugbank](https://vertexaisearch.cloud.google.com/id/1-24) [mdpi](https://vertexaisearch.cloud.google.com/id/1-25) [mylocalinfusion](https://vertexaisearch.cloud.google.com/id/1-26) [alzheimers](https://vertexaisearch.cloud.google.com/id/1-27) [alzheimersresearchuk](https://vertexaisearch.cloud.google.com/id/1-28) [wikipedia](https://vertexaisearch.cloud.google.com/id/1-29)selectively binds to soluble Aβ protofibrils, reducing Aβ protofibrils and amyloid plaques. Donanemab ta [nih](https://vertexaisearch.cloud.google.com/id/1-30) [japsonline](https://vertexaisearch.cloud.google.com/id/1-31) [patsnap](https://vertexaisearch.cloud.google.com/id/1-32) [wikipedia](https://vertexaisearch.cloud.google.com/id/1-29) [drugs](https://vertexaisearch.cloud.google.com/id/1-33)rgets a modified form of amyloid-beta found only in plaques, promoting plaque removal through microglial-mediated phagocytosis.\n*   **Donane [drugbank](https://vertexaisearch.cloud.google.com/id/1-24) [mdpi](https://vertexaisearch.cloud.google.com/id/1-25) [alzheimersresearchuk](https://vertexaisearch.cloud.google.com/id/1-28)mab vs Lecanemab:** Lecanemab targets amyloid as it begins to form fibers, while donanemab binds to amyloid once these fibers have clumped together to become a larger plaque.\n*   **Common [mylocalinfusion](https://vertexaisearch.cloud.google.com/id/1-26) [alzheimersresearchuk](https://vertexaisearch.cloud.google.com/id/1-28) Side Effects:** The most common side effects of lecanemab and donanemab include headache, infusion-related reactions, and amyloid-related imaging abnormalities (ARIA).\n*   **Effica [wikipedia](https://vertexaisearch.cloud.google.com/id/1-29) [drugbank](https://vertexaisearch.cloud.google.com/id/1-24)cy:** Both drugs have demonstrated modest efficacy in reducing cognitive decline compared to placebo in clinical trials.\n*   **Limita [wikipedia](https://vertexaisearch.cloud.google.com/id/1-29) [alzheimersresearchuk](https://vertexaisearch.cloud.google.com/id/1-28) [drugs](https://vertexaisearch.cloud.google.com/id/1-33) [nih](https://vertexaisearch.cloud.google.com/id/1-34) [mdpi](https://vertexaisearch.cloud.google.com/id/1-25) [nih](https://vertexaisearch.cloud.google.com/id/1-35) [drugbank](https://vertexaisearch.cloud.google.com/id/1-24)tions:**\n    *   **Administration:** Both donanemab and lecanemab are administered intravenously.\n    *   **Sa [alzheimers](https://vertexaisearch.cloud.google.com/id/1-27) [wikipedia](https://vertexaisearch.cloud.google.com/id/1-29) [alzheimersresearchuk](https://vertexaisearch.cloud.google.com/id/1-28) [drugbank](https://vertexaisearch.cloud.google.com/id/1-24)fety:** Both drugs are associated with ARIA. APOE ε4/ε4 h [nih](https://vertexaisearch.cloud.google.com/id/1-6) [nih](https://vertexaisearch.cloud.google.com/id/1-34) [mylocalinfusion](https://vertexaisearch.cloud.google.com/id/1-26) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-8) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-36) [drugbank](https://vertexaisearch.cloud.google.com/id/1-24) [nih](https://vertexaisearch.cloud.google.com/id/1-35) [wikipedia](https://vertexaisearch.cloud.google.com/id/1-29)omozygotes are at the highest risk of ARIAs.\n    *   **Cost [nih](https://vertexaisearch.cloud.google.com/id/1-6)-Effectiveness:** NICE has not recommended lecanemab for use on the NHS due to its high cost and limited benefits.\n\n**5. Advantag [syenza](https://vertexaisearch.cloud.google.com/id/1-23) [alzheimers](https://vertexaisearch.cloud.google.com/id/1-22) [alzheimers](https://vertexaisearch.cloud.google.com/id/1-27) [pharmaceutical-journal](https://vertexaisearch.cloud.google.com/id/1-21)es of Valiltramiprosate, AR1001, and Remternetug**\n\n*   **Valiltramiprosate and AR1001 (Oral Administration):** Offer a more convenient route of administration compared to the intravenous infusions required for donanemab and lecanemab.\n*   **Valiltra [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [alzheon](https://vertexaisearch.cloud.google.com/id/1-4) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0)miprosate (Safety Profile):** Has not been associated with an increased risk of ARIA, a known side effect of anti-amyloid monoclonal antibodies like donanemab and lecanemab.\n*   **Remterne [nih](https://vertexaisearch.cloud.google.com/id/1-6) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [firstwordpharma](https://vertexaisearch.cloud.google.com/id/1-7)tug (Efficacy):** May provide more robust plaque removal than donanemab.\n*   **Valiltra [alzheimersweekly](https://vertexaisearch.cloud.google.com/id/1-17)miprosate (Targeting APOE4 Homozygotes):** Being investigated for its potential in APOE ε4/ε4 homozygotes, a population at high risk for Alzheimer's disease and ARIA, and for whom some regulators limit the use of donanemab and lecanemab.\n*   **AR1001 (Po [nih](https://vertexaisearch.cloud.google.com/id/1-6) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-5) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-8) [researchgate](https://vertexaisearch.cloud.google.com/id/1-0) [acnr](https://vertexaisearch.cloud.google.com/id/1-9)lypharmacological Agent):** Acts through multiple mechanisms, including promoting neuronal cell survival and inhibiting Aβ accumulation.\n [researchgate](https://vertexaisearch.cloud.google.com/id/1-10) [clinicaltrialsarena](https://vertexaisearch.cloud.google.com/id/1-13) [neurologylive](https://vertexaisearch.cloud.google.com/id/1-14)"], 'sources_gathered': [{'label': 'fda', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkNUa83FDV1rsAZeUmHxYKV7fFceyGpabeU77PynE0Jt9W0IaJAKG830Jh2YY0p5H8bQA1Oj8x5Hn70aJRtw7TYwf4M902Wcpf88AKAobDNNZA9nlikHZsIxZMBbkiavFV-k6EZe4vUze1cvQygFYw8vnpcaZ7bi2BN0g5QmwpdhJXH7l6NrNArFze9dyOR8zm1FRrxKNaoJJU1QoQ'}, {'label': 'fda', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkNUa83FDV1rsAZeUmHxYKV7fFceyGpabeU77PynE0Jt9W0IaJAKG830Jh2YY0p5H8bQA1Oj8x5Hn70aJRtw7TYwf4M902Wcpf88AKAobDNNZA9nlikHZsIxZMBbkiavFV-k6EZe4vUze1cvQygFYw8vnpcaZ7bi2BN0g5QmwpdhJXH7l6NrNArFze9dyOR8zm1FRrxKNaoJJU1QoQ'}, {'label': 'fda', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEkNUa83FDV1rsAZeUmHxYKV7fFceyGpabeU77PynE0Jt9W0IaJAKG830Jh2YY0p5H8bQA1Oj8x5Hn70aJRtw7TYwf4M902Wcpf88AKAobDNNZA9nlikHZsIxZMBbkiavFV-k6EZe4vUze1cvQygFYw8vnpcaZ7bi2BN0g5QmwpdhJXH7l6NrNArFze9dyOR8zm1FRrxKNaoJJU1QoQ'}, {'label': 'alzint', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-1', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGOHJgPly4SmMT4HC36Q2SIE2XAYnAhHhiDB99l6Q0UXAb7iZfLFSUhFQdSQM4O4w11LnBeOfOnsDkGiS5nMKJKjgnPYLSLiGqnWyxsagOcs4fQyO8HHROyUiDenwkq9IhZ6VhYNtTTkNGO4l04IZmNRQqem-CUYvF2SjoIR7krPbCoUzwyUlBSHeBbXzdGTW0IfkRwDhCDrfZZCj0zDbPktVIbFZSv5Jgr'}, {'label': 'alzra', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-2', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9f9J8RlKOVC6_r2JwZpPjaB9GbBd6QP_ar6jZol8r7B9M29qCxoB4snm2MuG5r7a7V-1mAd_pco6i_Kc3OLH8G4ojhvYqP7ySrxb9LPcFKsxiD9MLfzDgZLUXopNJ3BJFTCmR6VFQF3bzEkCCkyX2cZDuc6_jN1pI4ylJwvdxSxA='}, {'label': 'practicalneurology', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-3', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFReQ-fbGFXjgxtqui1JJB3KcK4jiYO7BirLkvecjq4-eDZxm3ouPphiHzpJJm46mWmPYfFE3uKnA_qKOrxYKHGJJYE3btlEAmX7r7FT67ZTmx1Uono573Myppd0q-5lF_wvJ9KDNrYXKKTAWaZ7yginxmVsts5913rS8bwD_tETOV4aH8NgOcEyU0pO3eoXQlLxBsNMXlpoMB0t4JGnFLMtIURMYn20cI6msEBHndBRVq2n1c-WNULRg3TqpsCUWPH2O1F'}, {'label': 'eisai', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYJpAaftUjVuiD82MOAEueQfz2K9uhcCd7wKJXlHB7GxhM-LqNP61sTHfzGsW86YnAi6OykKbef-Nm15R4gvOR1coUQFdQAcpzWgXaxr7Rskl84iAQqg3CaXEqRpzxBYU0mAClFxY1NLJi'}, {'label': 'eisai', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-4', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYJpAaftUjVuiD82MOAEueQfz2K9uhcCd7wKJXlHB7GxhM-LqNP61sTHfzGsW86YnAi6OykKbef-Nm15R4gvOR1coUQFdQAcpzWgXaxr7Rskl84iAQqg3CaXEqRpzxBYU0mAClFxY1NLJi'}, {'label': 'stonybrookmedicine', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHijunFjIT2igGIfw3KFEW9-Cv_YX2jZ58eQuOcE-eUaahnOU08C-JWOdHYnvT0E8kUGudWfi_2oop8oDfHPFyd9hBxcA43dJKasF9sFqz8ZRCWGYF0QddAwOUe5Qwic3B1qS6TwUeMnfT50c8KIJNiYpzOidTHipGi1wTE2uIagJgBX8sQlCQOIr8XRy1WytFL7dri_B9BqlMwgFLEQ6xNs2ZA_Z-4q4m1FijaJFj-yJ4='}, {'label': 'k2med', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVtXk-oAB7R28HNgSTipcTwfuaT6gc0xTUuUhlJisZWSUzaNxBYibZy8WBCYzVVqjHZFfTaWBIsmocUzOCr1-Dmhcte3_ezEyWUBwkW2xwdgbUJBI3--SwCHIINAUx0J3oVQpiO7sXi_dG1kvT1g6xG2Qcd0YTGIuwZGlS53m6kDvAeuighqlB2WkN9doEJK-Q'}, {'label': 'k2med', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVtXk-oAB7R28HNgSTipcTwfuaT6gc0xTUuUhlJisZWSUzaNxBYibZy8WBCYzVVqjHZFfTaWBIsmocUzOCr1-Dmhcte3_ezEyWUBwkW2xwdgbUJBI3--SwCHIINAUx0J3oVQpiO7sXi_dG1kvT1g6xG2Qcd0YTGIuwZGlS53m6kDvAeuighqlB2WkN9doEJK-Q'}, {'label': 'k2med', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVtXk-oAB7R28HNgSTipcTwfuaT6gc0xTUuUhlJisZWSUzaNxBYibZy8WBCYzVVqjHZFfTaWBIsmocUzOCr1-Dmhcte3_ezEyWUBwkW2xwdgbUJBI3--SwCHIINAUx0J3oVQpiO7sXi_dG1kvT1g6xG2Qcd0YTGIuwZGlS53m6kDvAeuighqlB2WkN9doEJK-Q'}, {'label': 'k2med', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFVtXk-oAB7R28HNgSTipcTwfuaT6gc0xTUuUhlJisZWSUzaNxBYibZy8WBCYzVVqjHZFfTaWBIsmocUzOCr1-Dmhcte3_ezEyWUBwkW2xwdgbUJBI3--SwCHIINAUx0J3oVQpiO7sXi_dG1kvT1g6xG2Qcd0YTGIuwZGlS53m6kDvAeuighqlB2WkN9doEJK-Q'}, {'label': 'alzheimers', 'short_url': 'https://vertexaisearch.cloud.google.com/id/0-7', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEoKn-puqW5iqsqS60-3q89du-wxucNyQoQxSIE4c0nUSFa9SvYJddWXeRl1kGf7Th2IBh5cWbYyrIbGPGxuSWDubQPOV4cMUdPj757aCrwaasqwh10Isk5tow81SqBdDO4Kfd2Q-zPNqyysjiVd-SXCZEZWyTdeDc3eCSGacXhsXCTWWcDV8FX_GW1C8Ct8xulVc3SxnOwO6PJI0TaoUj99DGK6HxPnbN6Byyg3rs='}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'tandfonline', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE77xaCAdvmbxpdNX-AI9PxNKQfFsR14nOi1yxdZjILAx6Y-GBUTGQIggjmjBLl-REy1GD31exczgYyWNdjWRL6zQIYUWzF3UiPArV0fKZRwJVj4IkZTAtgDem_cf2I49A5WBZO8srGNn4uOqOmzdetbTdwMGgYFINiwvda'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHkg0V0FZiBMFiULaipaggOO7uy3voZ5pyUvAAoDS4YQU2IAdbsyUhh1zeu9WrYREgTJQxum3ayzfVJZZKOXRwvvRvUDE1Dsnks-ihQfaJsbLave1VWZaD65Qg-zbtY4beaStvk'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHkg0V0FZiBMFiULaipaggOO7uy3voZ5pyUvAAoDS4YQU2IAdbsyUhh1zeu9WrYREgTJQxum3ayzfVJZZKOXRwvvRvUDE1Dsnks-ihQfaJsbLave1VWZaD65Qg-zbtY4beaStvk'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'tandfonline', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE77xaCAdvmbxpdNX-AI9PxNKQfFsR14nOi1yxdZjILAx6Y-GBUTGQIggjmjBLl-REy1GD31exczgYyWNdjWRL6zQIYUWzF3UiPArV0fKZRwJVj4IkZTAtgDem_cf2I49A5WBZO8srGNn4uOqOmzdetbTdwMGgYFINiwvda'}, {'label': 'patsnap', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-3', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGlzWgh5MacUBI3dbXk6yC9ZBuzO6a1vQ2iYZdDWOlbYSMpHubkRsTytE4ZluV-QOzMNRQpef_bQ24yuxpWncg_eoFcg-Tgv4ODJa4yLygOKGRi0U74wyeK04mwdKrjhJisJIOCAh5CZ6GryOgR7aVE_2_HBf1SuyNQi2TD1pHdNYo='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHkg0V0FZiBMFiULaipaggOO7uy3voZ5pyUvAAoDS4YQU2IAdbsyUhh1zeu9WrYREgTJQxum3ayzfVJZZKOXRwvvRvUDE1Dsnks-ihQfaJsbLave1VWZaD65Qg-zbtY4beaStvk'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'alzheon', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3jvOCLH6EAcFaP7KazjBPLC3Do_OXVXBRuZSl5gGl2IJ304siWIUJ05Bfm8ulJKMVpXZc7-COU5gXz8BvbSeLNiq2Vi2rQjnXrOPmVBdFROAghuQFkhUEu3uCbNHStKmDE-P4XCx1AKnl'}, {'label': 'tandfonline', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE77xaCAdvmbxpdNX-AI9PxNKQfFsR14nOi1yxdZjILAx6Y-GBUTGQIggjmjBLl-REy1GD31exczgYyWNdjWRL6zQIYUWzF3UiPArV0fKZRwJVj4IkZTAtgDem_cf2I49A5WBZO8srGNn4uOqOmzdetbTdwMGgYFINiwvda'}, {'label': 'alzheon', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3jvOCLH6EAcFaP7KazjBPLC3Do_OXVXBRuZSl5gGl2IJ304siWIUJ05Bfm8ulJKMVpXZc7-COU5gXz8BvbSeLNiq2Vi2rQjnXrOPmVBdFROAghuQFkhUEu3uCbNHStKmDE-P4XCx1AKnl'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'alzheon', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3jvOCLH6EAcFaP7KazjBPLC3Do_OXVXBRuZSl5gGl2IJ304siWIUJ05Bfm8ulJKMVpXZc7-COU5gXz8BvbSeLNiq2Vi2rQjnXrOPmVBdFROAghuQFkhUEu3uCbNHStKmDE-P4XCx1AKnl'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9OpC1DOZtov3sRLJkidX0wInAEIMQLID6M5um6N2RRwJOkiZ--2xpkpdPnC-z3oBj4ASZ9ji1mKOzorBli60koCytT7jRF-afAP66tWt3i17HYihzzTEefXr-CIEroS2MN_NsOBcIEMrRwIW2'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'firstwordpharma', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGf8Gb46qHNLWBlXY8oYINGCWvsQ9fuB3bGbegxMhJzuNWLRM8yf8TlAcMTyM86qqzf3L72Bue6e4zsRlGI432Lp3j6x7SzEGvd9kwPgmTlkt4OfB79l3VmxiargVE1aTHROIsf'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9OpC1DOZtov3sRLJkidX0wInAEIMQLID6M5um6N2RRwJOkiZ--2xpkpdPnC-z3oBj4ASZ9ji1mKOzorBli60koCytT7jRF-afAP66tWt3i17HYihzzTEefXr-CIEroS2MN_NsOBcIEMrRwIW2'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYasYA1yDqbWerJOiiC1tQphR6TDfBbtgx4MXGB0QMqS-wnhiJPDQ5RjCMQfHwle-x9vuom3LizlhphZkLzTVls6CQOzUKXsQ1JBTuMvh5hBiZbMtnz3j6-8dfQ5Vy6smLncQ3a4bpkXiqVpAchGs2YqPsi3mT8h7W05IDtXLl_XgA6YS6TimeZ7Y0'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'acnr', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-9', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRpGlLAsE5EC1D3x0_GMAS_8rUW6JD7gH_eb_d56aOmRCizfmGScubSaDAEqNN74dFE1xUYLAMKCINIyzCpDhXh1eEjgmJsV2jIN8jDyTTOJ4b9sCyPBgvvvC0mCh22j4='}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYasYA1yDqbWerJOiiC1tQphR6TDfBbtgx4MXGB0QMqS-wnhiJPDQ5RjCMQfHwle-x9vuom3LizlhphZkLzTVls6CQOzUKXsQ1JBTuMvh5hBiZbMtnz3j6-8dfQ5Vy6smLncQ3a4bpkXiqVpAchGs2YqPsi3mT8h7W05IDtXLl_XgA6YS6TimeZ7Y0'}, {'label': 'firstwordpharma', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGf8Gb46qHNLWBlXY8oYINGCWvsQ9fuB3bGbegxMhJzuNWLRM8yf8TlAcMTyM86qqzf3L72Bue6e4zsRlGI432Lp3j6x7SzEGvd9kwPgmTlkt4OfB79l3VmxiargVE1aTHROIsf'}, {'label': 'tandfonline', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE77xaCAdvmbxpdNX-AI9PxNKQfFsR14nOi1yxdZjILAx6Y-GBUTGQIggjmjBLl-REy1GD31exczgYyWNdjWRL6zQIYUWzF3UiPArV0fKZRwJVj4IkZTAtgDem_cf2I49A5WBZO8srGNn4uOqOmzdetbTdwMGgYFINiwvda'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'firstwordpharma', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGf8Gb46qHNLWBlXY8oYINGCWvsQ9fuB3bGbegxMhJzuNWLRM8yf8TlAcMTyM86qqzf3L72Bue6e4zsRlGI432Lp3j6x7SzEGvd9kwPgmTlkt4OfB79l3VmxiargVE1aTHROIsf'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'tandfonline', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE77xaCAdvmbxpdNX-AI9PxNKQfFsR14nOi1yxdZjILAx6Y-GBUTGQIggjmjBLl-REy1GD31exczgYyWNdjWRL6zQIYUWzF3UiPArV0fKZRwJVj4IkZTAtgDem_cf2I49A5WBZO8srGNn4uOqOmzdetbTdwMGgYFINiwvda'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-2', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHkg0V0FZiBMFiULaipaggOO7uy3voZ5pyUvAAoDS4YQU2IAdbsyUhh1zeu9WrYREgTJQxum3ayzfVJZZKOXRwvvRvUDE1Dsnks-ihQfaJsbLave1VWZaD65Qg-zbtY4beaStvk'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'firstwordpharma', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGf8Gb46qHNLWBlXY8oYINGCWvsQ9fuB3bGbegxMhJzuNWLRM8yf8TlAcMTyM86qqzf3L72Bue6e4zsRlGI432Lp3j6x7SzEGvd9kwPgmTlkt4OfB79l3VmxiargVE1aTHROIsf'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'tandfonline', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE77xaCAdvmbxpdNX-AI9PxNKQfFsR14nOi1yxdZjILAx6Y-GBUTGQIggjmjBLl-REy1GD31exczgYyWNdjWRL6zQIYUWzF3UiPArV0fKZRwJVj4IkZTAtgDem_cf2I49A5WBZO8srGNn4uOqOmzdetbTdwMGgYFINiwvda'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'firstwordpharma', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGf8Gb46qHNLWBlXY8oYINGCWvsQ9fuB3bGbegxMhJzuNWLRM8yf8TlAcMTyM86qqzf3L72Bue6e4zsRlGI432Lp3j6x7SzEGvd9kwPgmTlkt4OfB79l3VmxiargVE1aTHROIsf'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIrRAh6Fb_veFv5fuP7q7xSDPtRQnLAs763eqNKdpECOitKgrFaTg1E3EDWxp62FeQrwoG6_XmhQzFmUbVQ066TRZp91fazpR01JMNmgCjMsO8DYM8ED6hDCS2TSvLeVSLuqEQfz9r-BoRlMGIiOLz7SD72lx3rnUboQsqQXn9_9JsWixOwjl8rjxdEjFivKgwDDZlBB3yZkKh4vZzyFNEcsYBeY_rUAqbCyKu6mDymN4YXPVcybKmzrO8U7CmyWtAyE8BUPTikyGpVnP0xW4uyuk='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-11', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxxy2JoA750rYPQcNOAfKnKXKh5SQslYcu8RMJX6fJAWja861i5D9j0JIt_6WaTxuAgrGT--9HLxhP3NojfuK9Ef_-YWUxSYpVyxMBYHLBg1KZHcVEVqukeljaG2OjQIXvXDQkzXr3g9CnbEwf'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIrRAh6Fb_veFv5fuP7q7xSDPtRQnLAs763eqNKdpECOitKgrFaTg1E3EDWxp62FeQrwoG6_XmhQzFmUbVQ066TRZp91fazpR01JMNmgCjMsO8DYM8ED6hDCS2TSvLeVSLuqEQfz9r-BoRlMGIiOLz7SD72lx3rnUboQsqQXn9_9JsWixOwjl8rjxdEjFivKgwDDZlBB3yZkKh4vZzyFNEcsYBeY_rUAqbCyKu6mDymN4YXPVcybKmzrO8U7CmyWtAyE8BUPTikyGpVnP0xW4uyuk='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-11', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxxy2JoA750rYPQcNOAfKnKXKh5SQslYcu8RMJX6fJAWja861i5D9j0JIt_6WaTxuAgrGT--9HLxhP3NojfuK9Ef_-YWUxSYpVyxMBYHLBg1KZHcVEVqukeljaG2OjQIXvXDQkzXr3g9CnbEwf'}, {'label': 'alzdiscovery', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-12', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQo_Q9qBuh9m6dC1A2K6f6rjG31ytV3MPMyXanR5YXk6zS-XChKOaXcKrPRhvYsnweScsoiDmyme7q6-gNjfBTuzuftLLgBVqY1x-cnAevwYszYiLpkqi-w3mbkpvcCnyHla9VF4OrwcSXbbE7pkMNO0ty1xuDj4GR33AXWc3xgUd9ug=='}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIrRAh6Fb_veFv5fuP7q7xSDPtRQnLAs763eqNKdpECOitKgrFaTg1E3EDWxp62FeQrwoG6_XmhQzFmUbVQ066TRZp91fazpR01JMNmgCjMsO8DYM8ED6hDCS2TSvLeVSLuqEQfz9r-BoRlMGIiOLz7SD72lx3rnUboQsqQXn9_9JsWixOwjl8rjxdEjFivKgwDDZlBB3yZkKh4vZzyFNEcsYBeY_rUAqbCyKu6mDymN4YXPVcybKmzrO8U7CmyWtAyE8BUPTikyGpVnP0xW4uyuk='}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIrRAh6Fb_veFv5fuP7q7xSDPtRQnLAs763eqNKdpECOitKgrFaTg1E3EDWxp62FeQrwoG6_XmhQzFmUbVQ066TRZp91fazpR01JMNmgCjMsO8DYM8ED6hDCS2TSvLeVSLuqEQfz9r-BoRlMGIiOLz7SD72lx3rnUboQsqQXn9_9JsWixOwjl8rjxdEjFivKgwDDZlBB3yZkKh4vZzyFNEcsYBeY_rUAqbCyKu6mDymN4YXPVcybKmzrO8U7CmyWtAyE8BUPTikyGpVnP0xW4uyuk='}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIrRAh6Fb_veFv5fuP7q7xSDPtRQnLAs763eqNKdpECOitKgrFaTg1E3EDWxp62FeQrwoG6_XmhQzFmUbVQ066TRZp91fazpR01JMNmgCjMsO8DYM8ED6hDCS2TSvLeVSLuqEQfz9r-BoRlMGIiOLz7SD72lx3rnUboQsqQXn9_9JsWixOwjl8rjxdEjFivKgwDDZlBB3yZkKh4vZzyFNEcsYBeY_rUAqbCyKu6mDymN4YXPVcybKmzrO8U7CmyWtAyE8BUPTikyGpVnP0xW4uyuk='}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-13', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFx9QxDl8j5ZHNH7x0Nq5dLIJQki4RW7Om2xa9XGsfr3FVXjopIRb8ERjuy4Oy4dw1xkjtPHVOslo8GlsDC8sz82mppXx_lUJPwia2ksL9GrDMyoNpGKGDudSnX1h8NAVx9CQpu69X6HrCCMKP_ENDq26Mcpp7RiDC8PsligueeHFT-ryMvAQasqBH0FlUP-Zjza7eAMZSrTh1YgnAdFlbHDmonmhJIt1ayVDPZloQG1m4jP6BVdqphS8YMsthowWXFG-L9qwFWcq6k_Op2'}, {'label': 'neurologylive', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-14', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHCTFBgehbaTcNpBudIKYTPrSzrRfoPgPX3G1vEIR1ExfyFwcV-_VzpTuB5rz8DvbqQMmORTJk1Watr1EL4xgNeVbPCkF7mlaqsjptumiyXix-CbArZnP_IjLdy2acOQWeqi3GjdOmrrjhQMdpZq3qJKxfpmm1DDhVA_Hp-nofAxbjpd4v-BK5CBm7eISI1r7ISZA72kRYsl7sOzeWl'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'tandfonline', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-1', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE77xaCAdvmbxpdNX-AI9PxNKQfFsR14nOi1yxdZjILAx6Y-GBUTGQIggjmjBLl-REy1GD31exczgYyWNdjWRL6zQIYUWzF3UiPArV0fKZRwJVj4IkZTAtgDem_cf2I49A5WBZO8srGNn4uOqOmzdetbTdwMGgYFINiwvda'}, {'label': 'alzdiscovery', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-12', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQo_Q9qBuh9m6dC1A2K6f6rjG31ytV3MPMyXanR5YXk6zS-XChKOaXcKrPRhvYsnweScsoiDmyme7q6-gNjfBTuzuftLLgBVqY1x-cnAevwYszYiLpkqi-w3mbkpvcCnyHla9VF4OrwcSXbbE7pkMNO0ty1xuDj4GR33AXWc3xgUd9ug=='}, {'label': 'alzdiscovery', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-12', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFQo_Q9qBuh9m6dC1A2K6f6rjG31ytV3MPMyXanR5YXk6zS-XChKOaXcKrPRhvYsnweScsoiDmyme7q6-gNjfBTuzuftLLgBVqY1x-cnAevwYszYiLpkqi-w3mbkpvcCnyHla9VF4OrwcSXbbE7pkMNO0ty1xuDj4GR33AXWc3xgUd9ug=='}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-13', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFx9QxDl8j5ZHNH7x0Nq5dLIJQki4RW7Om2xa9XGsfr3FVXjopIRb8ERjuy4Oy4dw1xkjtPHVOslo8GlsDC8sz82mppXx_lUJPwia2ksL9GrDMyoNpGKGDudSnX1h8NAVx9CQpu69X6HrCCMKP_ENDq26Mcpp7RiDC8PsligueeHFT-ryMvAQasqBH0FlUP-Zjza7eAMZSrTh1YgnAdFlbHDmonmhJIt1ayVDPZloQG1m4jP6BVdqphS8YMsthowWXFG-L9qwFWcq6k_Op2'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-11', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxxy2JoA750rYPQcNOAfKnKXKh5SQslYcu8RMJX6fJAWja861i5D9j0JIt_6WaTxuAgrGT--9HLxhP3NojfuK9Ef_-YWUxSYpVyxMBYHLBg1KZHcVEVqukeljaG2OjQIXvXDQkzXr3g9CnbEwf'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-11', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGxxy2JoA750rYPQcNOAfKnKXKh5SQslYcu8RMJX6fJAWja861i5D9j0JIt_6WaTxuAgrGT--9HLxhP3NojfuK9Ef_-YWUxSYpVyxMBYHLBg1KZHcVEVqukeljaG2OjQIXvXDQkzXr3g9CnbEwf'}, {'label': 'neurologylive', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-14', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHCTFBgehbaTcNpBudIKYTPrSzrRfoPgPX3G1vEIR1ExfyFwcV-_VzpTuB5rz8DvbqQMmORTJk1Watr1EL4xgNeVbPCkF7mlaqsjptumiyXix-CbArZnP_IjLdy2acOQWeqi3GjdOmrrjhQMdpZq3qJKxfpmm1DDhVA_Hp-nofAxbjpd4v-BK5CBm7eISI1r7ISZA72kRYsl7sOzeWl'}, {'label': 'clinrol', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-15', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE73munFd7cfyNVXnoRToXAfR3Vtbto2sOWLiCLD_N-55I3AlT23KuHFXBz4M1pK65_TXaiBAPCioviMwh7gOOhBAf09lktX4voQoC3tmdV7KFZ2nPqPraWMZMR7_c2wlWx59qz'}, {'label': 'clinicaltrials', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-16', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGTnJPff62vQylf7NSOqo--ZD1PX2INpqqfsMiteerjOvfqqrZOLWngHpJSCZ8HkV85aKcXp95BVL6RCV2nQO3oYsXdQUOB29AN15M5UH7s02uWSny3zhtS0mcovUlhtITSCWz4G2AR'}, {'label': 'alzheimersweekly', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-17', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFInzSBWtNkHwzwQFuX_-dhcJoF9UUwYsaquWCFh1Sy4cwpKrpMUHAwfssXd-28MhCOOoS4MMI1ZHKG0GU1CL06NlALPW2rqsYMU1GVpumk_vHN4vqPFFsKXoHWt7jklpaG1aO6emq7kfup5wA1II2qxfFeBoh_h2zNTdcE0Mw0elARBclQAq3yij6bTEs='}, {'label': 'innovareacademics', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-18', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFDFJOG6BcW2mQbafw1tLXwBPJ6hIFK5DjkasTFodZv0yWnpvJu4SUl93ge8PbQ14E8mCez5k4VQFA-gIEQWf9f-JLGaTgmcQW4xvJJ9hw4SDCctqLcd1bbGyzku037ObwcBsYFxLzcCxgfBfe4Uxb5_JQIFy2GluYOxR0Jse9TgawAdPdHp5JuYA=='}, {'label': 'beingpatient', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-19', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGsbAjz5Pw9tpo5LIW679YIqj8O4eMRrE_56rN6VbTgIhn6xBCyHhbCPaNC4gRLZgg9YWIMEerYDO2d5aV8NzA3lZjTRpXr39DpbwgT4eJ0IrBYZYnQe7q5L2JaoOJ0Xw-zBTegj3DPtoGoREDT4MROZhHnQnIb4ufsgA=='}, {'label': 'beingpatient', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-19', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGsbAjz5Pw9tpo5LIW679YIqj8O4eMRrE_56rN6VbTgIhn6xBCyHhbCPaNC4gRLZgg9YWIMEerYDO2d5aV8NzA3lZjTRpXr39DpbwgT4eJ0IrBYZYnQe7q5L2JaoOJ0Xw-zBTegj3DPtoGoREDT4MROZhHnQnIb4ufsgA=='}, {'label': 'alzheimersweekly', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-17', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFInzSBWtNkHwzwQFuX_-dhcJoF9UUwYsaquWCFh1Sy4cwpKrpMUHAwfssXd-28MhCOOoS4MMI1ZHKG0GU1CL06NlALPW2rqsYMU1GVpumk_vHN4vqPFFsKXoHWt7jklpaG1aO6emq7kfup5wA1II2qxfFeBoh_h2zNTdcE0Mw0elARBclQAq3yij6bTEs='}, {'label': 'innovareacademics', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-18', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFDFJOG6BcW2mQbafw1tLXwBPJ6hIFK5DjkasTFodZv0yWnpvJu4SUl93ge8PbQ14E8mCez5k4VQFA-gIEQWf9f-JLGaTgmcQW4xvJJ9hw4SDCctqLcd1bbGyzku037ObwcBsYFxLzcCxgfBfe4Uxb5_JQIFy2GluYOxR0Jse9TgawAdPdHp5JuYA=='}, {'label': 'clinrol', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-15', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE73munFd7cfyNVXnoRToXAfR3Vtbto2sOWLiCLD_N-55I3AlT23KuHFXBz4M1pK65_TXaiBAPCioviMwh7gOOhBAf09lktX4voQoC3tmdV7KFZ2nPqPraWMZMR7_c2wlWx59qz'}, {'label': 'clinicaltrials', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-16', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGTnJPff62vQylf7NSOqo--ZD1PX2INpqqfsMiteerjOvfqqrZOLWngHpJSCZ8HkV85aKcXp95BVL6RCV2nQO3oYsXdQUOB29AN15M5UH7s02uWSny3zhtS0mcovUlhtITSCWz4G2AR'}, {'label': 'alzheimersweekly', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-17', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFInzSBWtNkHwzwQFuX_-dhcJoF9UUwYsaquWCFh1Sy4cwpKrpMUHAwfssXd-28MhCOOoS4MMI1ZHKG0GU1CL06NlALPW2rqsYMU1GVpumk_vHN4vqPFFsKXoHWt7jklpaG1aO6emq7kfup5wA1II2qxfFeBoh_h2zNTdcE0Mw0elARBclQAq3yij6bTEs='}, {'label': 'everyone', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-20', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHff0X51Fg-fp-wg7cTdKBjElcwnXj463XhwnCz0QhdJAF-B1OxlOjRXSZQiQ6Ukol7JqiVO24uQudg5lNK5fUrrW0ZSnlT8Hh844gpabbZ5FQDuIWA7jKkWlXwMeUl-ilWpwAIRsi9zzyJmg=='}, {'label': 'pharmaceutical-journal', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-21', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcr5y__WNuBYJIHG5Or7SuX7tgYAv0KKkvRaVz7EC5gRQhjHoNWNwn8kuXO06tCOZajXfxG7J54f6x7V33b6UPliLQYPfm_toPnEfpqOJBU5xuHBwdxaxR9UMMQKrtC9CElYOUTB73onMDcumEh-36efQ5y3DbyunUhT5MvGoqC609vX8T_-ge6xaeeSqxWlcy9R4guh0PXfL-crkEo1PT8E0eRy-zPHIWIj2uaU26w8HQfA6jD4DxUSkHR_YMPyKYXQ=='}, {'label': 'beingpatient', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-19', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGsbAjz5Pw9tpo5LIW679YIqj8O4eMRrE_56rN6VbTgIhn6xBCyHhbCPaNC4gRLZgg9YWIMEerYDO2d5aV8NzA3lZjTRpXr39DpbwgT4eJ0IrBYZYnQe7q5L2JaoOJ0Xw-zBTegj3DPtoGoREDT4MROZhHnQnIb4ufsgA=='}, {'label': 'alzheimers', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-22', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGo_-4ikE00VM4eyJwhBOMOo-ZmGqZafNUJzLTEzz7_W0-htyKy-fYFXxJha-viN7mliCcu6Fskk8Cf8SXcdEUszON4SFXpOJl6sQ5WcNO6JYAG-Hh6BtJaNK7a1u1STnQeVxwt1wh6oBGpdh1t46RpPrhNneILOkcPYncIsv14mCx0Oh8cBu98h8pJOIqICmdmNuSiLf9hNblCDNIpVOcX-cRsv8kvPUkAENhSfH0='}, {'label': 'syenza', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-23', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnFqv5U_9EoZkUu_Li_suzl3EiiWObqSVg2O2NIPn7TUK8kP0HfcUcdtuOPFepLV73ndXqaIhFnc2sQAtSU7KvSPcy7oY1L1pj4NxC-3QDI100lY7jSuptas-S6gXqH6bM9RJBCaEcFmg='}, {'label': 'alzheimersweekly', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-17', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFInzSBWtNkHwzwQFuX_-dhcJoF9UUwYsaquWCFh1Sy4cwpKrpMUHAwfssXd-28MhCOOoS4MMI1ZHKG0GU1CL06NlALPW2rqsYMU1GVpumk_vHN4vqPFFsKXoHWt7jklpaG1aO6emq7kfup5wA1II2qxfFeBoh_h2zNTdcE0Mw0elARBclQAq3yij6bTEs='}, {'label': 'everyone', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-20', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHff0X51Fg-fp-wg7cTdKBjElcwnXj463XhwnCz0QhdJAF-B1OxlOjRXSZQiQ6Ukol7JqiVO24uQudg5lNK5fUrrW0ZSnlT8Hh844gpabbZ5FQDuIWA7jKkWlXwMeUl-ilWpwAIRsi9zzyJmg=='}, {'label': 'syenza', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-23', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnFqv5U_9EoZkUu_Li_suzl3EiiWObqSVg2O2NIPn7TUK8kP0HfcUcdtuOPFepLV73ndXqaIhFnc2sQAtSU7KvSPcy7oY1L1pj4NxC-3QDI100lY7jSuptas-S6gXqH6bM9RJBCaEcFmg='}, {'label': 'alzheimersweekly', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-17', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFInzSBWtNkHwzwQFuX_-dhcJoF9UUwYsaquWCFh1Sy4cwpKrpMUHAwfssXd-28MhCOOoS4MMI1ZHKG0GU1CL06NlALPW2rqsYMU1GVpumk_vHN4vqPFFsKXoHWt7jklpaG1aO6emq7kfup5wA1II2qxfFeBoh_h2zNTdcE0Mw0elARBclQAq3yij6bTEs='}, {'label': 'drugbank', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-24', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOMq_JEBwIaC81ei6QIJAKUsTSUOcF8ZmE0Jpzht8b45b_JNvT5N5K2mF4aJYbL2ABHKonpUzTOCNDSJ2B0GpCuTGZ0Y6ZRFr8ykZklGp9XcPeKFBIsgQe4M7czVeYs24='}, {'label': 'mdpi', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-25', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFevVY_ptqGu1zzk0D5qGJy5wRPWtE_Hu08vskqZ8FgdBQEJ-Oq7YI-CCdjeT06cWgR-io9vku7DIpF2GpsgXlDVn7Z9Uql4J3Juhg7o8w1rh0CsMpkRWigMN1rTPTRzpSh'}, {'label': 'mylocalinfusion', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-26', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGmUWx528NJaAS-7CCSO_brQJNCnvHm_xxRwRJDyRdIvi4W5N-fmIG4-Sqjnxpi9ZwdguKIbdrGqZq4aOq2rsE_iKYerLyrR2XMxe3Zj2mmISt4i-gF0DtnzpyOB52GOG9ItLA4-uiYEtD9GN_X7g=='}, {'label': 'alzheimers', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-27', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGO77shYY8bv4OMgiYJqTiNPODAyRpNTCZNmldCKQfvfVZRJOJfhrY28DkDnImlAKHRGWxtdgKcMg_h7tvVF8i3Jn61cjBXswg899h9yGgJ-k4GdjAH2-gIocVx9iXET5DyDIx1eYX14MdJJ69ikrJtDeYypetgx2WzohXdbwvY'}, {'label': 'alzheimersresearchuk', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-28', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHW_df3O5PhzxDs1hEhbvAaTx2Yj3aDS4GA8GVM1sXkNfCWucVxPE1-9IhseBEZnshaUWm6fxEt7_SMkuh7j_slCxKkOjbCAbI_bC2980lLWRsci-HFHt283W9JavRzwZZRocCb46jjIR8PPLwCER3AgoM0N8CCkM-3YLwwDccGDjROoOh2byoOBoCmgqIVZ9KPP7qtA0ch7SoiVTuqdOKVqrhY'}, {'label': 'wikipedia', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-29', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ULHAHXbXPoc6Z9_IfDcZHDkyBUP2HVM0MYResd5FI9MorNSajdGXTt_HCHybrN_8ch7Y1W47Sly87wAezCrhS2dABJ-EDKwjNS6Fz7Ppemy9fc8LUUZp6CgOIaN7kSdOkQ=='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-30', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH4zrEISukaY2K5VVGDe-dQpbpIoQYOLxtwSC37uEU5KpBGO7RxVEJR0P2-vn46mwAo2ms6LjBp7TtTZDX6E68JSSx4TqlLP119aI7ZlSUCkIY2QyCkRpvmKzqwSk5Wrr7xkeXo'}, {'label': 'japsonline', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-31', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGuDSR0LoxQJE8TayQX2OqKVEehnWaMfHZzZF9cuAVsor-tP8OI3u0WHjB3hoz2h0ZR13Jg6ditrtvsovL9ka6-796Hc9orRw8Neyew2ltNX-s2SC_HW2RWdTSYjuSDX5f3qPP1wmk9tcqDg1lZuV_G'}, {'label': 'patsnap', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-32', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFmtc0fgUZ8REeGkkK6nF-3ObfbJgG-E1_J4yN9Sk_ZjFMUATHlnbrQkXMh4eF10zdRLVOqfo3oL1MwTt5OutC9EvJdBb5NsJ78AfgJPebZU3wx8vpsWEipZPDYdbEyISVkkW_osfa7XvZSbFZK0J509TQt__auJ1VxphDFZXFU2Q0='}, {'label': 'wikipedia', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-29', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ULHAHXbXPoc6Z9_IfDcZHDkyBUP2HVM0MYResd5FI9MorNSajdGXTt_HCHybrN_8ch7Y1W47Sly87wAezCrhS2dABJ-EDKwjNS6Fz7Ppemy9fc8LUUZp6CgOIaN7kSdOkQ=='}, {'label': 'drugs', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-33', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGj2ZBqC9R0hhR0PfZK8TWLnniJOdrJCacy-TYuk0pSzCWtJItSi9kmfqc4x9mlnjuk-wBKAu0ekcXDEB0PiqhRmuKpjdxFPyNjYOGyV5wcbd5Ay4V6dqVbC6sWlJFIdzC4YqZl0SnyFBKwei5sY96qWs4ctu0gjivDxaOEeS2ZsWy483MAznOcr7H5rRZ16J46'}, {'label': 'drugbank', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-24', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOMq_JEBwIaC81ei6QIJAKUsTSUOcF8ZmE0Jpzht8b45b_JNvT5N5K2mF4aJYbL2ABHKonpUzTOCNDSJ2B0GpCuTGZ0Y6ZRFr8ykZklGp9XcPeKFBIsgQe4M7czVeYs24='}, {'label': 'mdpi', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-25', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFevVY_ptqGu1zzk0D5qGJy5wRPWtE_Hu08vskqZ8FgdBQEJ-Oq7YI-CCdjeT06cWgR-io9vku7DIpF2GpsgXlDVn7Z9Uql4J3Juhg7o8w1rh0CsMpkRWigMN1rTPTRzpSh'}, {'label': 'alzheimersresearchuk', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-28', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHW_df3O5PhzxDs1hEhbvAaTx2Yj3aDS4GA8GVM1sXkNfCWucVxPE1-9IhseBEZnshaUWm6fxEt7_SMkuh7j_slCxKkOjbCAbI_bC2980lLWRsci-HFHt283W9JavRzwZZRocCb46jjIR8PPLwCER3AgoM0N8CCkM-3YLwwDccGDjROoOh2byoOBoCmgqIVZ9KPP7qtA0ch7SoiVTuqdOKVqrhY'}, {'label': 'mylocalinfusion', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-26', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGmUWx528NJaAS-7CCSO_brQJNCnvHm_xxRwRJDyRdIvi4W5N-fmIG4-Sqjnxpi9ZwdguKIbdrGqZq4aOq2rsE_iKYerLyrR2XMxe3Zj2mmISt4i-gF0DtnzpyOB52GOG9ItLA4-uiYEtD9GN_X7g=='}, {'label': 'alzheimersresearchuk', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-28', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHW_df3O5PhzxDs1hEhbvAaTx2Yj3aDS4GA8GVM1sXkNfCWucVxPE1-9IhseBEZnshaUWm6fxEt7_SMkuh7j_slCxKkOjbCAbI_bC2980lLWRsci-HFHt283W9JavRzwZZRocCb46jjIR8PPLwCER3AgoM0N8CCkM-3YLwwDccGDjROoOh2byoOBoCmgqIVZ9KPP7qtA0ch7SoiVTuqdOKVqrhY'}, {'label': 'wikipedia', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-29', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ULHAHXbXPoc6Z9_IfDcZHDkyBUP2HVM0MYResd5FI9MorNSajdGXTt_HCHybrN_8ch7Y1W47Sly87wAezCrhS2dABJ-EDKwjNS6Fz7Ppemy9fc8LUUZp6CgOIaN7kSdOkQ=='}, {'label': 'drugbank', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-24', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOMq_JEBwIaC81ei6QIJAKUsTSUOcF8ZmE0Jpzht8b45b_JNvT5N5K2mF4aJYbL2ABHKonpUzTOCNDSJ2B0GpCuTGZ0Y6ZRFr8ykZklGp9XcPeKFBIsgQe4M7czVeYs24='}, {'label': 'wikipedia', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-29', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ULHAHXbXPoc6Z9_IfDcZHDkyBUP2HVM0MYResd5FI9MorNSajdGXTt_HCHybrN_8ch7Y1W47Sly87wAezCrhS2dABJ-EDKwjNS6Fz7Ppemy9fc8LUUZp6CgOIaN7kSdOkQ=='}, {'label': 'alzheimersresearchuk', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-28', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHW_df3O5PhzxDs1hEhbvAaTx2Yj3aDS4GA8GVM1sXkNfCWucVxPE1-9IhseBEZnshaUWm6fxEt7_SMkuh7j_slCxKkOjbCAbI_bC2980lLWRsci-HFHt283W9JavRzwZZRocCb46jjIR8PPLwCER3AgoM0N8CCkM-3YLwwDccGDjROoOh2byoOBoCmgqIVZ9KPP7qtA0ch7SoiVTuqdOKVqrhY'}, {'label': 'drugs', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-33', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGj2ZBqC9R0hhR0PfZK8TWLnniJOdrJCacy-TYuk0pSzCWtJItSi9kmfqc4x9mlnjuk-wBKAu0ekcXDEB0PiqhRmuKpjdxFPyNjYOGyV5wcbd5Ay4V6dqVbC6sWlJFIdzC4YqZl0SnyFBKwei5sY96qWs4ctu0gjivDxaOEeS2ZsWy483MAznOcr7H5rRZ16J46'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-34', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEcsQMKEA5BGj6t9_ArgI38pLtg7_8qjWNC72y3bkNeBV4Oq4YlwkxgZUpv4CdDUiR9PcZgKeh6WBPKyklGw-W732QtxYqiBlo6T4-lg5_h6VmMTzUgftDVnzrpvBlHU9RW7qI19lOQqIIc-yTB'}, {'label': 'mdpi', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-25', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFevVY_ptqGu1zzk0D5qGJy5wRPWtE_Hu08vskqZ8FgdBQEJ-Oq7YI-CCdjeT06cWgR-io9vku7DIpF2GpsgXlDVn7Z9Uql4J3Juhg7o8w1rh0CsMpkRWigMN1rTPTRzpSh'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-35', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHa6_eRNa4oJhm5wZtYbEWIpKrKOlzJ0bDxpH3-PLXcrVvXIuSJggbiXVpF_aqZEoS6D4A4OMwtvq0o5_q0CFa4r6mCSriK5U2lLJvMQj01CBoxIxyvCzvYB-z3Eqv1HSY15p8w-gc0pXIKAhY6'}, {'label': 'drugbank', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-24', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOMq_JEBwIaC81ei6QIJAKUsTSUOcF8ZmE0Jpzht8b45b_JNvT5N5K2mF4aJYbL2ABHKonpUzTOCNDSJ2B0GpCuTGZ0Y6ZRFr8ykZklGp9XcPeKFBIsgQe4M7czVeYs24='}, {'label': 'alzheimers', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-27', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGO77shYY8bv4OMgiYJqTiNPODAyRpNTCZNmldCKQfvfVZRJOJfhrY28DkDnImlAKHRGWxtdgKcMg_h7tvVF8i3Jn61cjBXswg899h9yGgJ-k4GdjAH2-gIocVx9iXET5DyDIx1eYX14MdJJ69ikrJtDeYypetgx2WzohXdbwvY'}, {'label': 'wikipedia', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-29', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ULHAHXbXPoc6Z9_IfDcZHDkyBUP2HVM0MYResd5FI9MorNSajdGXTt_HCHybrN_8ch7Y1W47Sly87wAezCrhS2dABJ-EDKwjNS6Fz7Ppemy9fc8LUUZp6CgOIaN7kSdOkQ=='}, {'label': 'alzheimersresearchuk', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-28', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHW_df3O5PhzxDs1hEhbvAaTx2Yj3aDS4GA8GVM1sXkNfCWucVxPE1-9IhseBEZnshaUWm6fxEt7_SMkuh7j_slCxKkOjbCAbI_bC2980lLWRsci-HFHt283W9JavRzwZZRocCb46jjIR8PPLwCER3AgoM0N8CCkM-3YLwwDccGDjROoOh2byoOBoCmgqIVZ9KPP7qtA0ch7SoiVTuqdOKVqrhY'}, {'label': 'drugbank', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-24', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOMq_JEBwIaC81ei6QIJAKUsTSUOcF8ZmE0Jpzht8b45b_JNvT5N5K2mF4aJYbL2ABHKonpUzTOCNDSJ2B0GpCuTGZ0Y6ZRFr8ykZklGp9XcPeKFBIsgQe4M7czVeYs24='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9OpC1DOZtov3sRLJkidX0wInAEIMQLID6M5um6N2RRwJOkiZ--2xpkpdPnC-z3oBj4ASZ9ji1mKOzorBli60koCytT7jRF-afAP66tWt3i17HYihzzTEefXr-CIEroS2MN_NsOBcIEMrRwIW2'}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-34', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEcsQMKEA5BGj6t9_ArgI38pLtg7_8qjWNC72y3bkNeBV4Oq4YlwkxgZUpv4CdDUiR9PcZgKeh6WBPKyklGw-W732QtxYqiBlo6T4-lg5_h6VmMTzUgftDVnzrpvBlHU9RW7qI19lOQqIIc-yTB'}, {'label': 'mylocalinfusion', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-26', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGmUWx528NJaAS-7CCSO_brQJNCnvHm_xxRwRJDyRdIvi4W5N-fmIG4-Sqjnxpi9ZwdguKIbdrGqZq4aOq2rsE_iKYerLyrR2XMxe3Zj2mmISt4i-gF0DtnzpyOB52GOG9ItLA4-uiYEtD9GN_X7g=='}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYasYA1yDqbWerJOiiC1tQphR6TDfBbtgx4MXGB0QMqS-wnhiJPDQ5RjCMQfHwle-x9vuom3LizlhphZkLzTVls6CQOzUKXsQ1JBTuMvh5hBiZbMtnz3j6-8dfQ5Vy6smLncQ3a4bpkXiqVpAchGs2YqPsi3mT8h7W05IDtXLl_XgA6YS6TimeZ7Y0'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-36', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHRDBViV1MR3FNmQ9vxg1gja6F_G5FoN0pnVF6IckIFvQyFO7PigMBOx3_iVKavDMdxxjON48ieRq6fzmzM7W6dzHMBfYx7tMuqKtR8ohzt9QHeQ3_UY3XzUtGO99HVZS9fOyv-VP3Jqr7FPeMqcE26IuM-hVwpDzs='}, {'label': 'drugbank', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-24', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFOMq_JEBwIaC81ei6QIJAKUsTSUOcF8ZmE0Jpzht8b45b_JNvT5N5K2mF4aJYbL2ABHKonpUzTOCNDSJ2B0GpCuTGZ0Y6ZRFr8ykZklGp9XcPeKFBIsgQe4M7czVeYs24='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-35', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHa6_eRNa4oJhm5wZtYbEWIpKrKOlzJ0bDxpH3-PLXcrVvXIuSJggbiXVpF_aqZEoS6D4A4OMwtvq0o5_q0CFa4r6mCSriK5U2lLJvMQj01CBoxIxyvCzvYB-z3Eqv1HSY15p8w-gc0pXIKAhY6'}, {'label': 'wikipedia', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-29', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQG7ULHAHXbXPoc6Z9_IfDcZHDkyBUP2HVM0MYResd5FI9MorNSajdGXTt_HCHybrN_8ch7Y1W47Sly87wAezCrhS2dABJ-EDKwjNS6Fz7Ppemy9fc8LUUZp6CgOIaN7kSdOkQ=='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9OpC1DOZtov3sRLJkidX0wInAEIMQLID6M5um6N2RRwJOkiZ--2xpkpdPnC-z3oBj4ASZ9ji1mKOzorBli60koCytT7jRF-afAP66tWt3i17HYihzzTEefXr-CIEroS2MN_NsOBcIEMrRwIW2'}, {'label': 'syenza', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-23', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGnFqv5U_9EoZkUu_Li_suzl3EiiWObqSVg2O2NIPn7TUK8kP0HfcUcdtuOPFepLV73ndXqaIhFnc2sQAtSU7KvSPcy7oY1L1pj4NxC-3QDI100lY7jSuptas-S6gXqH6bM9RJBCaEcFmg='}, {'label': 'alzheimers', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-22', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGo_-4ikE00VM4eyJwhBOMOo-ZmGqZafNUJzLTEzz7_W0-htyKy-fYFXxJha-viN7mliCcu6Fskk8Cf8SXcdEUszON4SFXpOJl6sQ5WcNO6JYAG-Hh6BtJaNK7a1u1STnQeVxwt1wh6oBGpdh1t46RpPrhNneILOkcPYncIsv14mCx0Oh8cBu98h8pJOIqICmdmNuSiLf9hNblCDNIpVOcX-cRsv8kvPUkAENhSfH0='}, {'label': 'alzheimers', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-27', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGO77shYY8bv4OMgiYJqTiNPODAyRpNTCZNmldCKQfvfVZRJOJfhrY28DkDnImlAKHRGWxtdgKcMg_h7tvVF8i3Jn61cjBXswg899h9yGgJ-k4GdjAH2-gIocVx9iXET5DyDIx1eYX14MdJJ69ikrJtDeYypetgx2WzohXdbwvY'}, {'label': 'pharmaceutical-journal', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-21', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHcr5y__WNuBYJIHG5Or7SuX7tgYAv0KKkvRaVz7EC5gRQhjHoNWNwn8kuXO06tCOZajXfxG7J54f6x7V33b6UPliLQYPfm_toPnEfpqOJBU5xuHBwdxaxR9UMMQKrtC9CElYOUTB73onMDcumEh-36efQ5y3DbyunUhT5MvGoqC609vX8T_-ge6xaeeSqxWlcy9R4guh0PXfL-crkEo1PT8E0eRy-zPHIWIj2uaU26w8HQfA6jD4DxUSkHR_YMPyKYXQ=='}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'alzheon', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-4', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF3jvOCLH6EAcFaP7KazjBPLC3Do_OXVXBRuZSl5gGl2IJ304siWIUJ05Bfm8ulJKMVpXZc7-COU5gXz8BvbSeLNiq2Vi2rQjnXrOPmVBdFROAghuQFkhUEu3uCbNHStKmDE-P4XCx1AKnl'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9OpC1DOZtov3sRLJkidX0wInAEIMQLID6M5um6N2RRwJOkiZ--2xpkpdPnC-z3oBj4ASZ9ji1mKOzorBli60koCytT7jRF-afAP66tWt3i17HYihzzTEefXr-CIEroS2MN_NsOBcIEMrRwIW2'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'firstwordpharma', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-7', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGf8Gb46qHNLWBlXY8oYINGCWvsQ9fuB3bGbegxMhJzuNWLRM8yf8TlAcMTyM86qqzf3L72Bue6e4zsRlGI432Lp3j6x7SzEGvd9kwPgmTlkt4OfB79l3VmxiargVE1aTHROIsf'}, {'label': 'alzheimersweekly', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-17', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFInzSBWtNkHwzwQFuX_-dhcJoF9UUwYsaquWCFh1Sy4cwpKrpMUHAwfssXd-28MhCOOoS4MMI1ZHKG0GU1CL06NlALPW2rqsYMU1GVpumk_vHN4vqPFFsKXoHWt7jklpaG1aO6emq7kfup5wA1II2qxfFeBoh_h2zNTdcE0Mw0elARBclQAq3yij6bTEs='}, {'label': 'nih', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-6', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9OpC1DOZtov3sRLJkidX0wInAEIMQLID6M5um6N2RRwJOkiZ--2xpkpdPnC-z3oBj4ASZ9ji1mKOzorBli60koCytT7jRF-afAP66tWt3i17HYihzzTEefXr-CIEroS2MN_NsOBcIEMrRwIW2'}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-5', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFJeuprO13PVeJD-SSay4AFu9s_d3XlkyyPLgJZoCb_dKjYDm_yGwrAj3ZZFWhiZ9G0whyInVJCh9uzS2XUxejgXy4OpBSlA0mRkNxDUmSwbVtMdeUT_YW1X8G0qHgqyjcm1caDsg3AvT2x101ePOVWFWwZcdg6GBcGFTMe-mwjeBpd_FsUf6ezsWy8SZ8C0cIGKAy8vPL3V8G1_rwR3Q=='}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-8', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGYasYA1yDqbWerJOiiC1tQphR6TDfBbtgx4MXGB0QMqS-wnhiJPDQ5RjCMQfHwle-x9vuom3LizlhphZkLzTVls6CQOzUKXsQ1JBTuMvh5hBiZbMtnz3j6-8dfQ5Vy6smLncQ3a4bpkXiqVpAchGs2YqPsi3mT8h7W05IDtXLl_XgA6YS6TimeZ7Y0'}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-0', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGNp_84P63nX365tsmcqcLuyXMzo9PDg3Gw_vyNfCpxolNWzYdu-Oz482RB3RdQ8esymVR9dKVbFKeWDHNCVXqzHR97G_32Q7TOamPVgzqOqZw9CwO6tdG0UQOieWOFTVOa5ASH6iqAIrUkRAP9yhVFIOFGGyxPp88oJdVU8Dvi19CQrCeRWPntpdH4Xf8OmzEGf8EcPol1vRDs62srcArwngh7JauR7i45fJnANh_rrTAcq4BZcODwaOJA6ySKyuDI43oAgvqW1V9DHUVPMzjmXHU3m2iW324wKgxHh7oocVRApF-F-VjCDtJ3bLeXdsjrbHg='}, {'label': 'acnr', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-9', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGRpGlLAsE5EC1D3x0_GMAS_8rUW6JD7gH_eb_d56aOmRCizfmGScubSaDAEqNN74dFE1xUYLAMKCINIyzCpDhXh1eEjgmJsV2jIN8jDyTTOJ4b9sCyPBgvvvC0mCh22j4='}, {'label': 'researchgate', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-10', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFIrRAh6Fb_veFv5fuP7q7xSDPtRQnLAs763eqNKdpECOitKgrFaTg1E3EDWxp62FeQrwoG6_XmhQzFmUbVQ066TRZp91fazpR01JMNmgCjMsO8DYM8ED6hDCS2TSvLeVSLuqEQfz9r-BoRlMGIiOLz7SD72lx3rnUboQsqQXn9_9JsWixOwjl8rjxdEjFivKgwDDZlBB3yZkKh4vZzyFNEcsYBeY_rUAqbCyKu6mDymN4YXPVcybKmzrO8U7CmyWtAyE8BUPTikyGpVnP0xW4uyuk='}, {'label': 'clinicaltrialsarena', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-13', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFx9QxDl8j5ZHNH7x0Nq5dLIJQki4RW7Om2xa9XGsfr3FVXjopIRb8ERjuy4Oy4dw1xkjtPHVOslo8GlsDC8sz82mppXx_lUJPwia2ksL9GrDMyoNpGKGDudSnX1h8NAVx9CQpu69X6HrCCMKP_ENDq26Mcpp7RiDC8PsligueeHFT-ryMvAQasqBH0FlUP-Zjza7eAMZSrTh1YgnAdFlbHDmonmhJIt1ayVDPZloQG1m4jP6BVdqphS8YMsthowWXFG-L9qwFWcq6k_Op2'}, {'label': 'neurologylive', 'short_url': 'https://vertexaisearch.cloud.google.com/id/1-14', 'value': 'https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHCTFBgehbaTcNpBudIKYTPrSzrRfoPgPX3G1vEIR1ExfyFwcV-_VzpTuB5rz8DvbqQMmORTJk1Watr1EL4xgNeVbPCkF7mlaqsjptumiyXix-CbArZnP_IjLdy2acOQWeqi3GjdOmrrjhQMdpZq3qJKxfpmm1DDhVA_Hp-nofAxbjpd4v-BK5CBm7eISI1r7ISZA72kRYsl7sOzeWl'}], 'initial_search_query_count': 3, 'max_research_loops': 3, 'research_loop_count': 2}